#United States #Louisville #Eflornithine #US WorldMeds #Orbus Therapeutics

US WorldMeds Merges with Orbus Therapeutics

In a significant move to enhance its portfolio in the field of rare diseases, US WorldMeds Ventures, LLC has finalized a merger with Orbus Therapeutics, Inc. This acquisition allows US WorldMeds to incorporate Orbus's promising investigational drug, eflornithine, targeted at treating adult malignant gliomas, notably recurrent Grade 3 astrocytomas.

This strategic acquisition is not just a business transaction; it reflects US WorldMeds' firm commitment to addressing the unmet needs of patients suffering from rare and serious health conditions. By adding Orbus's late-stage program to its repertoire, US WorldMeds is set to advance its mission of providing innovative treatment solutions to underserved populations.

Eflornithine, known scientifically as DFMO, is an oral drug that inhibits ornithine decarboxylase (ODC), an enzyme that plays a crucial role in cellular proliferation. Elevated levels of this enzyme are often associated with various cancers, making it a valid target for therapeutic intervention. The FDA has already granted Breakthrough Therapy designation to eflornithine for the treatment of anaplastic astrocytoma, signaling its potential in oncology.

The acquisition was motivated by the results of the Phase 3 STELLAR study, which demonstrated clinically meaningful improvements in both overall survival and progression-free survival among patients with recurrent IDH-mutant Grade 3 astrocytoma. Although the overall intent-to-treat population did not show survival benefits compared to lomustine alone, the subset analysis provided compelling evidence that eflornithine, when used in conjunction with lomustine, significantly enhances patient outcomes for this particular group.

According to the STELLAR study results:

• - The median overall survival for patients receiving the eflornithine-lomustine combination was 34.9 months, compared to 23.5 months for those who received lomustine alone.
• - Median progression-free survival reported was also promising, with 15.8 months for the combination therapy, against 7.2 months for lomustine alone.

While the study did encounter some treatment-emergent adverse events—such as myelosuppression and hearing impairment—these were considered manageable and indicative of the complexity and seriousness of treating this type of glioma. The findings of the STELLAR trial have since been published in the Journal of Clinical Oncology, contributing to a growing body of peer-reviewed knowledge surrounding the treatment of gliomas.

P. Breckinridge Jones, CEO of US WorldMeds, expressed excitement regarding the acquisition, emphasizing that their company is built around providing meaningful therapies for difficult-to-treat diseases. He noted, "The science and clinical results supporting eflornithine make this an especially compelling opportunity for US WorldMeds." He believes that with the company’s expertise in commercialization, they can effectively advance the program through its next clinical chapters.

As for the future of eflornithine, US WorldMeds plans to closely evaluate the drug's development and regulatory pathway, particularly for its application in IDH-mutant Grade 3 astrocytomas. The company is dedicated to engaging with the FDA to explore the best approaches for facilitating this important work, indicating a proactive effort to increase treatment options for patients grappling with such challenging malignancies.

US WorldMeds continues to focus on building a portfolio that encompasses rare oncological diseases and various specialty areas. With the acquisition of Orbus Therapeutics, they are not only expanding their capabilities but also reaffirming their commitment to improving patient outcomes in settings where they are starkly needed.

This merger signifies a leap forward in addressing the challenges presented by rare diseases, illuminating a path toward hope and enhanced therapies for patients facing malignant gliomas. As US WorldMeds moves forward, its collaboration with Orbus sets the stage for potentially transformative advancements in the field of oncology.